In this video, health-care analysts David Williamson and Max Macaluso discuss four big headlines impacting some of the most popular stocks in the space. Watch and find out what it all means for investors.

 

The biotech space can make or destroy investors overnight, and Amarin, with its potential blockbuster drug, will be no different. The company has huge potential, but don't invest today before reading everything you need to know about Amarin. You can start now with top Fool.com analyst Max Macaluso's premium research report. Click here to keep reading. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.